US FDA approves Lantheus' brain-imaging agent for Alzheimer's assessment

The U.S. Food and Drug Administration has ​approved a radioactive agent from ‌Lantheus Holdings for use in brain scans to help assess patients for ​Alzheimer's disease, the company ​said on Friday.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。